Inbrain Neuroelectronics S.L., a Barcelona, Spain-based company dedicated to developing an intelligent graphene-brain interface, raised $16.8m in Series A funding.
The round was co-led by Asabys Partners and Alta Life Sciences, and joined by Vsquared Ventures and TruVenturo GmbH, with the participation of the Spanish Ministry of Science’s CDTI and a follow-on investment by the Institut Català de Finances’ ICF Venture Tech II fund.
The company intends to use the funds to advance its first-in-human clinical program, aiming to establish the safety of graphene as the new standard of care for neurotechnology devices.
Founded in 2019 by CEO Carolina Aguilar, and Chief Scientific Officer Jose Garrido, Inbrain Neuroelectronics is a medical device company dedicated to developing an intelligent graphene-brain interface to treat a variety of conditions. Its first product is designed to read and modulate brain activity, using artificial intelligence to trigger adaptive responses for personalized neurological therapy for epilepsy and Parkinson’s disease.